As previously reported, Baird analyst David Rescott initiated coverage of Inari Medical with an Outperform rating and $79 price target. The firm forecasts an 18% revenue growth outlook for Inari over the next two years as the company continues to drive rising adoption of mechanical thrombectomy in VTE markets and thinks multiple expansion toward the comp group is “warranted,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NARI:
- Inari Medical initiated with an Outperform at Baird
- Inari Medical to Announce Second Quarter 2023 Financial Results
- Penumbra price target raised to $376 from $325 at Deutsche Bank
- Inari Medical Announces the Release of 2022 Ethos and Sustainability Report
- Inari Medical Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism Patients